AMI works to improve infectious disease control and prevention using promising practices, innovations, and lessons learned. Find information on AMI's framework of six interventions below.

In collaboration with the Amazon Network for the Surveillance of Antimalarial Drug Resistance (Red Amazónica para la Vigilancia de la Resistencia a los Antimaláricos, or RAVREDA), AMI has established a network of sentinel sites for ongoing surveillance of drug efficacy in Amazon countries using standardized protocols.
Fact Sheet: Antimalarial Medicine Resistance AMI led the development of guidelines and recommendations for improving diagnostic quality assurance/quality control (QA/QC) systems in the Amazon Basin subregion. AMI has promoted increased awareness about antimalarial drug quality issues among all Amazon countries and has encouraged the development of a quality system for drugs used in the national malaria control programs in these countries.
Fact Sheet: Antimalarial Medicine Quality In collaboration with national malaria control programs, AMI technical partners have systematically intervened at each step of the pharmaceutical management cycle to institutionalize best practices meant to improve the access to and use of antimalarial medicines in the partner countries. Fact Sheet: Antimalarial Medicine Access and Use
AMI seeks to improve the development and implementation of vector control strategies in the Amazon countries by promoting the rational selection of vector control measures and through improved efforts to detect the presence of malaria vector mosquitoes that are not susceptible to certain insecticides. Communication and information dissemination are vital components of each problem area addressed by AMI. To share its success stories and lessons learned throughout the subregion, AMI’s communication component targets diverse audiences, including the general public, policymakers, healthcare providers, and technical and scientific audiences.